文献速递湿疹皮炎与荨麻疹

H1抗组胺药难治性慢性自发性荨麻疹药物治疗的系统评价与网络荟萃分析

Evaluation of Pharmacologic Treatments for H1 Antihistamine-Refractory Chronic Spontaneous Urticaria: A Systematic Review and Network Meta-analysis.
PubMed 文献 · JAMA Dermatol · 2021-01-01

结果显示ligelizumab 72mg和240mg及omalizumab 300mg和600mg可有效改善荨麻疹症状,治疗不可接受性无显著差异。

要点

  • ligelizumab 72mg和240mg对荨麻疹症状改善为大效应
  • omalizumab 300mg和600mg对荨麻疹症状改善为中等效应
  • 各治疗间治疗不可接受性无显著差异

核心结论

  • 生物制剂ligelizumab 72mg或240mg及omalizumab 300mg或600mg可推荐用于H1抗组胺药反应不足的慢性自发性荨麻疹患者。

研究设计与样本

  • 系统评价与网络荟萃分析,检索MEDLINE、Embase、PubMed、Cochrane Library、Web of Science、Scopus和CINAHL从建库至2021年4月19日,无语言限制。

主要发现

  • 荨麻疹症状变化的标准化均数差:ligelizumab 72mg为-1.05(95%CI,-1.37至-0.73)。
  • ligelizumab 240mg为-1.07(95%CI,-1.39至-0.75)。
  • omalizumab 300mg为-0.77(95%CI,-0.91至-0.63)。
  • omalizumab 600mg为-0.59(95%CI,-1.10至-0.08)。
  • 治疗不可接受性无显著差异。

关键数值与推荐

  • 主要结局包括荨麻疹症状自基线的变化和治疗不可接受性(全因脱落)。
  • 网络估计显示ligelizumab 72mg或240mg为大效应获益,omalizumab 300mg或600mg为中等效应获益。

临床怎么用

  • 对H1抗组胺药反应不足的慢性自发性荨麻疹患者,可考虑使用ligelizumab 72mg或240mg或omalizumab 300mg或600mg。

局限性

  • 需要高质量、设计和方法学一致的头对头试验,以帮助制定后续国际指南。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The comparative benefits and harms of all available treatments for H1 antihistamine-refractory chronic spontaneous urticaria (CSU) have not been established. OBJECTIVE: To evaluate different treatment effects of pharmacologic treatments among patients with H1 antihistamine-refractory CSU. DATA SOURCES: Searches were conducted of MEDLINE, Embase, PubMed, Cochrane Library, Web of Science, Scopus, and CINAHL from inception to April 19, 2021, with no language restrictions. Gray literature from Google Scholar, ongoing trial registers, and preprint reports was added to the searches of electronic databases. STUDY SELECTION: Randomized clinical trials using validated measurement tools that investigated the benefits and harms of pharmacologic treatments among adolescent or adult patients with CSU who had an inadequate response to H1 antihistamines were screened for inclusion independently by 2 investigators. DATA EXTRACTION AND SYNTHESIS: Two investigators independently extracted study data according to the predefined list of interests. A random-effects model was used to calculate the network estimates reported as standardized mean differences and odds ratios with corresponding 95% CIs. MAIN OUTCOMES AND MEASURES: The primary outcomes that reflect the patient's perspective included changes in urticaria symptoms from baseline and unacceptability of treatment (all-cause dropouts). RESULTS: Twenty-three randomized clinical trials with 2480 participants that compared 18 different interventions or dosages and placebo were included. The standardized mean differences for change in urticaria symptoms were -1.05 (95% CI, -1.37 to -0.73) for ligelizumab, 72 mg; -1.07 (95% CI, -1.39 to -0.75) for ligelizumab, 240 mg; -0.77 (95% CI, -0.91 to -0.63) for omalizumab, 300 mg; and -0.59 (95% CI, -1.10 to -0.08) for omalizumab, 600 mg. No significant differences in treatment unacceptability were observed. With respect to benefits and harms, the network estimates illustrated that the most efficacious treatments were achieved with ligelizumab, 72 or 240 mg (large beneficial effect) and omalizumab, 300 or 600 mg (moderate beneficial effect). CONCLUSIONS AND RELEVANCE: The findings in this meta-analysis suggest that the biologic agents ligelizumab, 72 or 240 mg, and omalizumab, 300 or 600 mg, can be recommended as effective treatments for patients with CSU who have had an inadequate response to H1 antihistamines. Head-to-head trials with high methodologic quality and harmonized design and outcome definitions are needed to help inform subsequent international guidelines for the management of CSU.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Nochaiwong S, Chuamanochan M, Ruengorn C, et al. Evaluation of Pharmacologic Treatments for H1 Antihistamine-Refractory Chronic Spontaneous Urticaria: A Systematic Review and Network Meta-analysis. JAMA Dermatol. 2021. PMID: 34431983. doi:10.1001/jamadermatol.2021.3237

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。